NCT00171873View on ClinicalTrials.gov

Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut

PHASE3CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

September 30, 2001

Primary Completion Date

June 30, 2008

Study Completion Date

December 31, 2013

Conditions
Neuroendocrine Tumors
Interventions
DRUG

Octreotide LAR (Long-acting release)

30 mg intramuscularly every 28 days

DRUG

Placebo

Sodium chloride intramuscularly every 28 days

Trial Locations (10)

35033

Novartis Investigative Site, Marburg

Unknown

Novartis Investigative Site, Bochum

Novartis Investigative Site, Dresden

Novartis Investigative Site, Halle

Novartis Investigative Site, Hamburg

Novartis Investigative Site, Kiel

Novartis Investigative Site, Leipzig

Novartis Investigative Site, Mainz

Novartis Investigative Site, Marburg

Novartis Investigative Site, München

All Listed Sponsors
lead

Carmen Schade-Brittinger

OTHER

NCT00171873 - Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut | Biotech Hunter | Biotech Hunter